Highlights Jiangsu Recbio Technology Co., Ltd.

Equities

2179

CNE1000057K9

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
8.52 ^CNY	-5.33%		-5.23%	-21.55%

May. 08	Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director	CI
Mar. 27	Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	Mar. 26	CI
Jiangsu Recbio Technology's Loss Narrows in 2023	Mar. 21	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	Dec. 28	CI
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	23-07-26	CI
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	23-04-20	MT
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Jiangsu Recbio Technology Co., Ltd. Announces Completion of the First Batch of Subject Enrollment for the Phase I Clinical Trial of Novel Adjuvanted Recombinant Shingles Vaccine REC610	23-02-13	CI
China's Securities Regulator Accepts Jiangsu Recbio's Application for Shares Issuance	23-02-08	MT
Jiangsu Recbio Technology Co., Ltd. Achieves Positive Results for its Sequential Booster Vaccination Phase II Study of the Recombinant Two-Component COVID-19 Vaccine ReCOV in the Philippines	22-12-25	CI
Jiangsu Recbio Technology Co., Ltd. Announces That Positive Results Were Achieved for Its Sequential Booster Vaccination Phase Ii Study of the Recombinant Two-Component Covid-19 Vaccine Recov in the Philippines	22-12-23	CI
Philippine Drug Regulator Approves Jiangsu Recbio's Clinical Trial for Shingles Vaccine; Shares Slip 8%	22-12-19	MT
Jiangsu Recbio Technology Co., Ltd. Announces Clinical Trial Approval for the Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	22-12-19	CI
Jiangsu Recbio Technology Co., Ltd Announces Positive Results Were Achieved for Its Sequential Booster Vaccination Phase Ii Study of the Recombinant Twocomponent COVID-19 Vaccine Recov in the Philippines	22-12-14	CI
Jiangsu Recbio Technology Co., Ltd. Increases Production for the First Phase of Manufacturing Facility with a Maximum Annual Output of 20 Million Doses of Recombinant HPV 9-Valent Vaccine	22-11-21	CI
Jiangsu Recbio Technology Co., Ltd Announces Update on Overseas Clinical Trials Progress of Novel Adjuvant COVID-19 Vaccine ReCOV	22-11-08	CI
Jiangsu Recbio Technology Co., Ltd. Completes the First Batch of Subject Enrollment for the International Multi-Center Phase Iii Clinical Trial of Recombinant Covid-19 Vaccine Recov	22-11-07	CI
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results of Multiple Overseas Phase II Clinical Trials of Recombinant Covid-19 Vaccine Recov	22-11-07	CI
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of the Application for Clinical Trial of Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine	22-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jiangsu Recbio Technology Co., Ltd.

Equities

2179

CNE1000057K9

Highlights

Filters